Amgen Inc. (NASDAQ:AMGN) is considered one of the most undervalued blue chip stocks to buy, with UBS analyst raising price target to $326. The company is expected to deliver a small beat in Q2 results, focusing on rare disease products. Amgen is a biotech firm specializing in therapies for complex cancers. While it’s a solid investment, AI stocks may offer greater potential. No promotional content included.

Read more at Yahoo Finance: UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating